Correction to: Nature Biotechnology, published online 9 November 2021.

This News article has been updated to reflect that AstraZeneca is pursuing a Treg cell therapy research program, not CAR-Treg, and that the company’s validation experiments following a genome-wide screen looking for additional factors that can help ensure a consistent Treg phenotype are at the planning stage, not ongoing, as the article states.

The online version of the article has been updated.